Vitiligo is a chronic pigmentary disorder in which melanocytes are destroyed, causing depigmented patches of skin and sometimes hair. It is often associated with autoimmune mechanisms.
AbbVie posted record 2025 revenue of $61.2 billion and raised 2026 guidance on Skyrizi and Rinvoq growth. Pipeline advances include Crohn's submissions, obesity data, and European approval for Boey.
AbbVie raised 2026 revenue and EPS guidance after first-quarter results beat estimates, with Skyrizi and Rinvoq driving growth. Humira erosion continued as neuroscience, oncology and pipeline assets supported the outlook.
Arcutis is in focus after new Phase 3 extension data for Zoryve cream 0.05% in young children with atopic dermatitis and ahead of its Feb. 25 Q4 results. Investors are also watching recent FDA actions and pipeline updates for additional pediatric and dermatology indications.
AbbVie said Skyrizi and Rinvoq generated $26.0 billion in 2025 sales and are expected to exceed $31 billion in 2026. The company said the two immunology drugs continue to offset Humira erosion and drive top-line growth.
Two phase 3 trials found upadacitinib 15 mg significantly improved facial and total repigmentation versus placebo at 48 weeks in nonsegmental vitiligo. The 614-patient studies also showed continued improvement over time and a safety profile consistent with prior use.
Incyte executives presented a post-Jakafi growth strategy at the Barclays conference, outlining four product launches and pipeline progress in hematology, immunology, and solid tumors ahead of Jakafi's loss of exclusivity in 2029.
Arcutis Biotherapeutics is scheduled to report fourth-quarter and full-year 2025 results on Feb. 25, after market close. Investors will focus on sales performance of Zoryve and pipeline updates.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07748169 |
An Observational Study of Patients With Dermatologic Disease |
RECRUITING | |
| NCT07682506 |
A Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Non-segmental Vitiligo |
RECRUITING | PHASE3 |
| NCT07659418 |
PPDTM CorEvitasTM Vitiligo Drug Safety and Effectiveness Registry for Adults & Adolescents |
ENROLLING_BY_INVITATION | |
| NCT07647237 |
A Clinical Trial of Multiple Doses of GR2301 Injection Combined With Phototherapy in Trial Participants With Vitiligo |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07625891 |
Study of D-2570 in Subjects With Non-Segmental Vitiligo |
RECRUITING | PHASE2 |
| NCT07595939 |
Efficacy and Safety of Ruxolitinib Cream in Chinese Children Aged 2-11 Years With Non-segmental Vitiligo |
NOT_YET_RECRUITING | PHASE3 |
| NCT07533019 |
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo |
RECRUITING | PHASE2 |
| NCT07353801 |
Oral Mini Pulse Dexamethasone in Pediatric Vitiligo |
ACTIVE_NOT_RECRUITING | PHASE4 |
| NCT07352293 |
The Value of Methotrexate in NCES for Stable Vitiligo |
ACTIVE_NOT_RECRUITING | PHASE4 |
| NCT07181187 |
Phase II Clinical Trial of MH004 Ointment in Patients With Non-segmental Vitiligo |
COMPLETED | PHASE2 |
